贝福替尼(D-0316)在既往EGFR酪氨酸激酶抑制剂治疗后进展的EGFR T790M突变NSCLC患者中的疗效与安全性:一项2期、多中心、单臂、开放标签研究
这项2期多中心单臂开放标签研究在中国大陆49家医院评估贝福替尼治疗一/二代EGFR TKI进展后T790M突变晚期NSCLC,A组50mg共176例、B组75-100mg共290例。B组独立评审ORR为67.6%,研究者评估中位PFS A组11.0个月、B组12.5个月,B组≥3级治疗相关不良事件29.3%。
要点
- B组75-100mg独立评审ORR为67.6%(95%CI 61.9%-72.9%),研究者评估A组54.0%、B组65.9%。
- 研究者评估中位PFS:A组11.0个月,B组12.5个月。
- B组≥3级治疗相关不良事件29.3%,治疗相关严重不良事件10.0%。
核心结论
- 贝福替尼75-100mg对一/二代EGFR TKI耐药后T790M突变晚期NSCLC显示出令人满意的疗效和可控的毒性。
- 一项3期随机试验正在进行(NCT04206072)。
研究设计与样本
- 单臂、开放标签、2期研究,在中国大陆49家医院开展。
- 纳入局部晚期或转移性NSCLC、既往一/二代EGFR TKI治疗后进展且携带EGFR T790M突变的患者。
- 患者口服贝福替尼50mg(A组)或75-100mg(B组)每日一次。
- 主要终点为独立评审委员会在意向治疗人群中评估的客观缓解率。
- A组176例,B组290例。
主要发现
- 数据截止2021年8月15日,B组独立评审ORR为67.6%(95%CI 61.9%-72.9%)。
- 研究者评估ORR:A组54.0%(95%CI 46.3%-61.5%),B组65.9%(95%CI 60.1%-71.3%)。
- 研究者评估中位PFS:A组11.0个月(95%CI 9.6-12.5),B组12.5个月(95%CI 11.1-13.8)。
- B组独立评审中位PFS为16.6个月(95%CI 15.0-不可评估)。
- 颅内ORR:A组研究者评估26.7%(95%CI 7.8%-55.1%);B组研究者评估57.1%(95%CI 34.0%-78.2%),独立评审55.9%(95%CI 37.9%-72.8%)。
关键数值与推荐
- A组颅内中位PFS研究者评估为16.5个月(95%CI 8.6-不可评估)。
- B组颅内中位PFS因数据不成熟,无论研究者或独立评审评估均不可评估。
- 总生存数据不成熟。
- ≥3级治疗相关不良事件:A组20.5%,B组29.3%;治疗相关严重不良事件:A组11.4%,B组10.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy. METHODS: This was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression after prior first- or second-generation EGFR TKI therapy received oral befotertinib of 50 mg (cohort A) or 75 to 100 mg (cohort B) once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156. RESULTS: A total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75-100 mg), respectively. At data cutoff (August 15, 2021), independent review committee-assessed ORR was 67.6% (95% confidence interval [CI]: 61.9%-72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%-61.5%) in cohort A and 65.9% (95% CI: 60.1%-71.3%) in cohort B. The median investigator-assessed progression-free survival was 11.0 (95% CI: 9.6-12.5) months in cohort A and 12.5 (95% CI: 11.1-13.8) months in cohort B. The median independent review committee-assessed progression-free survival in cohort B was 16.6 (95% CI: 15.0-not evaluable [NE]) months. The intracranial ORR was 26.7% (95% CI: 7.8%-55.1%) in cohort A by investigator assessment, while 57.1% (95% CI: 34.0%-78.2%) and 55.9% (95% CI: 37.9%-72.8%) in cohort B by investigator and independent review committee assessment, respectively. The median investigator-assessed intracranial progression-free survival was 16.5 (95% CI: 8.6-NE) months in cohort A, while the median intracranial progression-free survival was not evaluable in cohort B due to immature data regardless of investigator or independent review committee assessment. and NE (95% CI: 13.8-NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A and in 29.3% and 10.0% of patients in cohort B, respectively. CONCLUSIONS: Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first- or second-generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072).
引用
- Lu S, Zhang Y, Zhang G, et al. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. J Thorac Oncol. 2022. PMID: 35724798. doi:10.1016/j.jtho.2022.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。